Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DALLAS and FORT WORTH, Texas, March 08, 2018 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report fourth quarter and year-end 2017 financial results prior to the opening of U.S. financial markets on Thursday, March 15, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5653457. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
[email protected]
Sarah McCabe
Senior Vice President
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
